AI-Designed Universal Coronavirus Vaccine Passes First Human Trial
Researchers at the University of Cambridge announced June 5 that an AI-designed universal coronavirus vaccine passed its first human trial safely. The vaccine generated immune responses against multiple coronavirus strains, including SARS-CoV-2 and related bat viruses, in 39 healthy volunteers.
Scientists at the University of Cambridge and the spinout company DIOSynVax announced on June 5, 2026, that an AI-designed universal coronavirus vaccine had cleared its first human clinical trial safely and produced immune responses against multiple coronavirus strains.
The Phase 1 study enrolled 39 healthy volunteers between the ages of 18 and 50 at research facilities in Southampton and Cambridge. No significant side effects or serious adverse events were reported. The vaccine stimulated immune responses against SARS-CoV-2, SARS, and related bat coronaviruses, including strains the participants had never been exposed to.
Unlike conventional vaccines that target a specific viral strain, this vaccine uses an AI-generated "super-antigen." Researchers used machine learning to analyze global genetic data from the Sarbeco coronavirus family, identifying structural features that remain consistent across different strains. By targeting those shared regions, the vaccine aims to provide broad protection that holds up even as viruses mutate.
The vaccine was delivered using a needle-free micro-fluid jet system, which researchers said could speed up large-scale vaccination campaigns.
The results are considered a milestone, but the vaccine is not ready for public use. Larger Phase 2 and Phase 3 trials are needed to confirm real-world efficacy. Researchers also noted that the regulatory pathway for a universal vaccine remains undefined, since current FDA frameworks are built around strain-specific shots.
The same AI-driven design system is now being applied to develop potential vaccines for influenza, Ebola, and other hemorrhagic fever viruses.
